

报告人黄涛博士简历



黄涛博士，千骥资本的合伙人，专注千骥资本在美国的新药研发，诊断技术，以及医疗仪器方面的投资，并负责投资企业的商务，法务和知识产权战略。黄涛博士也是 NeuCyte, Inc.，的总裁和联合创始人。NeuCyte 是美国硅谷一家专注于神经系统疾病新药研发的生物制药公司。黄涛博士毕业于北京协和医学院（生物化学博士）和密歇根大学法学院（法律博士），并在普林斯顿大学做博士后研究。拥有 20 多年的生物医学研究、法律、和风险投资的经验。加入千骥资本之前黄涛博士曾任职于几家美国律师事务所，包括 WSGR 和摩根路易斯，为生物医药公司和投资者提供法律和商务咨询。

Dr. Tao HUANG has over 20 years of combined experience in biomedical research, legal, academia and the life sciences industry. At Cenova, he oversees the intellectual property (“IP”) strategy for the portfolio companies. Prior to Cenova, Dr. Huang was an attorney at several prestigious law firms in the US, including Wilson Sonsini Goodrich and Rosati, and Morgan Lewis and Bockius. He has advised companies and investors in the biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent counselling, licensing, litigation, venture financing, mergers and acquisitions, and initial public offerings. Dr. Huang has provided IP and legal representation to several notable business transactions, including Takeda’s licensing and collaboration deal with Alnylam relating to RNAi therapeutics, Ion Torrent’s acquisition by Life Technologies, and QuantaLife’s acquisition by Bio-Rad Laboratories.

Dr. Huang received a B.Sc. in Biophysics from Nankai University, a Ph.D. in Biochemistry from Peking Union Medical College's Chinese Academy of Medical Sciences, a J.D. from the University of Michigan Law School and obtained his post-doctoral training in molecular biology and biochemistry from Princeton University. Dr. Huang is a registered United States Patent and Trademark Office attorney in the state of California.